TY - JOUR
T1 - The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder
AU - Heres Diddens, Andreas
AU - Kraaijenga, Sophie
AU - Coupé, Veerle
AU - Hilgers, Frans
AU - van der Molen, Lisette
AU - Smeele, Ludi
AU - Retèl, Valesca
PY - 2017/9/3
Y1 - 2017/9/3
N2 - Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.Results: The point estimate for the incremental cost-effectiveness ratio is −28,068 EUR (−30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.
AB - Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.Results: The point estimate for the incremental cost-effectiveness ratio is −28,068 EUR (−30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.
KW - Cost-effectiveness
KW - Mandibular function
KW - Orofacial pain
KW - Physical therapy
KW - Quality of life (QoL)
KW - Temporomandibular disorder
KW - TheraBite
KW - Trismus
KW - n/a OA procedure
UR - http://www.scopus.com/inward/record.url?scp=84987851017&partnerID=8YFLogxK
U2 - 10.1080/08869634.2016.1232344
DO - 10.1080/08869634.2016.1232344
M3 - Article
C2 - 27630036
AN - SCOPUS:84987851017
SN - 0886-9634
VL - 35
SP - 290
EP - 297
JO - Cranio - Journal of Craniomandibular Practice
JF - Cranio - Journal of Craniomandibular Practice
IS - 5
ER -